New Triple-Pronged attack on aggressive breast cancer shows promise
NCT ID NCT07471815
Summary
This study is testing whether adding two drugs—an immunotherapy (camrelizumab) and a bone-strengthening medication (risedronate)—to standard chemotherapy works better against triple-negative breast cancer. The goal is to overcome treatment resistance, shrink tumors more effectively, and help patients live longer. It will involve about 30 women with this specific type of breast cancer to see if the three-drug combination is safe and effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 158100, China
Conditions
Explore the condition pages connected to this study.